



Post-cryoablation magnetic resonance imaging features of desmoid tumors: a pictorial essay

 Leonor G. Savarese¹

 Nicolas Papalexis²

 Marco Miceli²

 Michela Carta²

 Giancarlo Facchini²

¹University of Sao Paulo, Ribeirao Preto Medical School, Department of Medical Imaging, Hematology and Clinical Oncology, Ribeirão, Brazil

²IRCCS Istituto Ortopedico Rizzoli, Diagnostic and Interventional Radiology Unit, Bologna, Italy

ABSTRACT

Desmoid tumors (DTs) are rare, locally aggressive soft tissue neoplasms with highly variable clinical behavior. Although benign, their infiltrative nature can lead to considerable morbidity. DTs present a major challenge due to their unpredictable behavior and potential for misdiagnosis. Recently, there has been a large shift in the treatment strategy for DTs, and the number of cases being followed up with imaging has increased. Cryoablation has emerged as a minimally invasive treatment option, yet post-procedural imaging features remain poorly characterized. This study illustrates the magnetic resonance imaging (MRI) evolution of DTs following percutaneous cryoablation, emphasizing key patterns across pre-treatment, intra-procedural, and follow-up studies. The available MRI follow-up ranged from 6 to 30 months. Through a pictorial approach, we aimed to provide radiologists with practical insights to avoid misinterpretation of expected post-treatment changes as recurrence and to improve clinical management.

KEYWORDS

Desmoid tumor, magnetic resonance imaging, follow-up studies, soft tissue neoplasm, ablation technique, cryoablation, radiology, interventional

Desmoid-type fibromatosis, also known as desmoid tumor (DT) or aggressive fibromatosis, is a rare, locally invasive fibroblastic proliferation characterized by an unpredictable clinical course.^{1,2} These tumors account for < 3% of soft tissue neoplasms, with an incidence of approximately 3–5 cases per million annually. They typically affect individuals in their third to fourth decades of life and show a higher prevalence in women. Most cases are sporadic and arise in extra-abdominal locations, particularly the extremities and trunk.³

DTs pose a major diagnostic and management challenge due to their variable behavior, which can range from rapid growth to spontaneous regression. Recent guidelines emphasize an initial surveillance strategy to prevent overtreatment, reserving intervention for symptomatic or progressive cases. However, a decision to initiate therapy earlier may be considered when DTs are located near critical structures, as there may be a higher risk of morbidity before the disease stabilizes. When treatment is warranted, options include systemic therapies (such as chemotherapy or tyrosine kinase inhibitors) and local interventions.^{4,5}

Cryoablation has emerged as a promising local therapy and is now included in updated management guidelines. This minimally invasive technique employs cryoprobes to induce tumor cell death through extreme cold, achieved via the Joule–Thomson effect. Cellular destruction results from intracellular ice formation and vascular injury, leading to ischemia. Image-guided cryoablation, typically performed under computed tomography guidance, allows precise visualization of a low-attenuation ice ball in soft tissues, providing visual confirmation that the tumor is included in the cryoablated volume.⁶ Recent studies have shown that image-guided percutaneous cryoablation appears to be safe and effective for local control in

Handling editor: Bahri Üstünsöz

Corresponding author: Leonor G. Savarese

E-mail: lsavarese@hcrp.usp.br

Received 10 June 2025; revision requested 21 July 2025;
last revision received 05 October 2025; accepted 24
October 2025.



Epub: 08.12.2025

Publication date: 01.09.2026

DOI: 10.4274/dir.2025.253499

You may cite this article as: Savarese LG, Papalexis N, Miceli M, Carta M, Facchini G. Post-cryoablation magnetic resonance imaging features of desmoid tumors: a pictorial essay. *Diagn Interv Radiol*. 2026;32(5):709-714.

patients with extra-abdominal DTs.⁷⁻¹¹ In this pictorial essay, we illustrate six representative cases of extra-abdominal DTs treated with percutaneous cryoablation, including three men and three women (age range 33–54 years). Tumor sites comprise the gluteal region (n = 2), lumbar wall (n = 1), abdominal wall (n = 1), scapular region (n = 1), and calf (n = 1) (Table 1).

Role of magnetic resonance imaging

Magnetic resonance imaging (MRI) plays a critical role in the diagnosis, treatment planning, and follow-up of DTs. Imaging findings correlate with histopathologic features; hyperintense areas on T2-weighted and enhancing sequences reflect high cellularity, whereas hypointense, non-enhancing regions correspond to fibrous, low-cellularity components.^{12,13} An increase in collagenization within the tumor is associated with a decrease in cellularity, suggesting a reduction in tumor activity. This can be seen on MRI as a decrease in enhancement and T2 hyperintensity, which are imaging features indicating a positive response to therapy.¹⁴

Post-cryoablation imaging findings

Post-cryoablation MRI findings evolve. In early follow-up, considerable edema may be noted in the cryoablation area and adjacent soft tissues (Figure 1). Early imaging signs after the procedure include a non-enhancing ablation cavity with a high T2 signal, corresponding to coagulative necrosis. A thin inner rim of low T2 signal, indicative of hemosiderin rim (hemorrhagic congestion), can be better visualized on T2 gradient echo sequences. A thicker outer rim of intermediate/low T2 signal with post-contrast enhancement corresponds to granulation tissue/vascular fibrosis (Figure 2).

In subsequent follow-ups, the non-enhancing ablation cavity shows a size reduc-

tion and may show a marked decrease in T2 signal intensity, indicative of dense fibrosis. Additionally, a progressive reduction in post-contrast enhancement of the outer rim of granulation tissue/vascular fibrosis can be noted (Figure 3). Finally, a reduction in lesion volume is expected in successful cases (Figure 4), with a progressive replacement by adipose tissue observed in subcutaneous cases (Figure 5). If tumor recurrence occurs, it can be observed on post-contrast sequences as a nodular enhancing area (Figure 2). Imaging findings are summarized in Table 2.

The success rate of cryoablation is directly related to the ice ball encompassing the entire lesion during the procedure. However, cryoablation may induce the “abscopal effect,” leading to the reduction or disappearance of the tumor in non-frozen sites, possibly due to immune modulation (Figure 6). This phenomenon is of high importance in tumor therapy, as it effectively reduces the likelihood of tumor recurrence.¹⁵

Diffusion-weighted imaging (DWI) correlates with the content of the treated tissue, showing higher apparent diffusion coefficient (ADC) values in cases of low cellularity and fibrous content. It can also be used to detect changes in the treated tissue post-cryoablation. A recent article¹⁶ reported low ADC values (mean $0.90 \times 10^3 \text{ mm}^2/\text{s}$) in early follow-up of treated tissue after cryotherapy, possibly due to tumor necrosis. This should not be confused with recurrence, especially when no enhancement is present. Further studies are needed to confirm DWI patterns

in treated tissue post-cryoablation. However, this pattern was also observed in some cases in this study, as shown in Figure 7.

Discussion

The management of DTs has become increasingly individualized, tailored around patients’ needs and lesions’ features. Aggressive surgical approaches are generally avoided in favor of more conservative, minimally invasive strategies.¹⁷ The current consensus has shifted towards a “watch-and-wait” first-line approach, and intervention is performed for progressive or symptomatic cases.^{11,17} In this context, image-guided percutaneous cryoablation has emerged as a valuable and minimally invasive alternative to surgery and systemic therapy.¹⁸

Recent studies have shown encouraging outcomes in terms of local control and symptom relief, especially when complete tumor coverage is achieved during ablation.¹⁹ This, combined with minimal side effects, has led to its inclusion in recent international guidelines.^{11,17-19} Furthermore, the potential for cryoablation to induce systemic antitumor effects—the so-called abscopal effect—suggests opportunities for synergy with systemic therapies, including immunotherapy.²⁰

Despite these advancements, standardized radiologic criteria for treatment response remain lacking. MRI features, such as transient T2 hyperintensity or DWI changes, may mimic recurrence, especially in early follow-up, if not properly contextualized.²¹

Table 1. Patients’ demographics and characteristics

Case	Age (years)	Sex	Tumor location	Magnetic resonance imaging follow-up duration (months)
1	35	Male	Right gluteal region	18
2	54	Female	Right lumbar subcutaneous region	30
3	48	Female	Left abdominal wall	8
4	33	Male	Left gluteal subcutaneous region	25
5	50	Female	Left scapular region	18
6	33	Female	Calf	6

Table 2. Key magnetic resonance imaging findings after cryoablation of desmoid tumors

Imaging feature	Definition/description
Non-enhancing ablation cavity	Central zone without enhancement, corresponding to coagulative necrosis
Hemosiderin rim	Thin inner rim of low T2 signal due to hemorrhagic congestion
Granulation tissue/vascular fibrosis	Outer rim with intermediate/high T2 signal and post-contrast enhancement
Progressive fibrosis	Reduction in T2 signal and enhancement over time
Nodular enhancement	New or growing enhancing nodule at cavity margin, suspicious for recurrence

Main points

- Magnetic resonance imaging (MRI) is fundamental in the post-cryoablation follow-up of desmoid tumors, enabling precise differentiation between expected treatment-related changes and tumor recurrence.
- Key imaging findings after cryoablation include a central non-enhancing cavity, peripheral granulation tissue with contrast enhancement, and progressive fibrosis reflected by decreasing T2 signal intensity.
- Recognizing the temporal evolution of these MRI features is essential to avoid misinterpretation and to guide appropriate clinical decision-making.




Figure 1. A 35-year-old man. Axial T2 fat-sat imaging (a) reveals a desmoid tumor in the right gluteal region (asterisk). A computed tomography scan taken during the procedure, axial (b) and reconstructed coronal (c) views, shows cryoprobes placed within the lesion, with the ice ball (yellow arrows) covering the entire tumor as well as a safety margin of healthy tissue. In the early follow-up, 1 week post-procedure, considerable edema was noted in the cryoablation area and adjacent soft tissues. A well-demarcated zone of edema (white arrows in d) that extends beyond the lesion's margins, encompassing the gluteal muscles and the iliac bone, corresponds to the area covered by the ice ball. Note the thermoprotection of the skin, achieved by using sterile gloves filled with warmed saline and a subcutaneous injection of air (arrowheads in b, c).




Figure 2. A 35-year-old man. Axial T2 fat-sat/short tau inversion recovery (STIR) (a-d) and post-contrast T1 fat-sat images (e-h) of a desmoid tumor in the right gluteal region, pre- and post-cryoablation, across different time frames (a, e: pre-treatment; b, f: 3 months; c, g: 9 months; d, h: 18 months). At the 3-month follow-up, a non-enhancing ablation cavity corresponding to the ablation cavity was observed (asterisk), displaying a markedly low signal on T2 fat-sat/STIR, suggestive of dense fibrosis, and surrounded by granulation tissue/vascular fibrosis with post-contrast enhancement (white arrows). The 9-month follow-up revealed a potential recurrence at the anterior margin of the ablation cavity, more clearly delineated on the post-contrast T1 fat-sat sequence as a nodular enhancing area (yellow arrow). By the 18-month follow-up, this enhancing nodular lesion had increased in size, extending to the medial and posterior margins, confirming the recurrence (yellow arrows).




Figure 3. A 54-year-old woman. Axial T2 fat-sat (a-e) and post-contrast T1 (f) and T1 fat-sat (g-j) imaging of a subcutaneous desmoid tumor in the right lumbar area, pre- and post-cryoablation, at different time frames (a, f: pre-treatment; b, g: 2 months; c, h: 7 months; d, i: 13 months; e, j: 30 months). In the 2 months post-procedure images, note a non-enhancing ablation cavity with high T2 signal at the lesion's center, indicative of coagulative necrosis (asterisk). It is surrounded by an inner thin rim of low T2 signal (arrowheads) corresponding to a hemosiderin rim (hemorrhagic congestion) and an outer rim of high T2 signal and post-contrast enhancement (arrows) corresponding to granulation tissue/vascular fibrosis. In subsequent follow-ups, the non-enhancing ablation cavity exhibits a reduction in size and a marked decrease in T2 signal intensity, indicative of dense fibrosis. A progressive reduction in the post-contrast enhancement of the outer rim of granulation tissue/vascular fibrosis can also be seen.




Figure 4. A 48-year-old woman. Axial T2 with fat-sat (a-c), axial T1 fat-sat post-contrast (d-f), and T2 gradient echo (g) of a left abdominal wall desmoid tumor, pre- and post-cryoablation, at different time frames (a, d: pre-treatment; b, e, g: 1 month; c, f: 8 months). In the images taken 1 month post-procedure, note a non-enhancing ablation cavity with high T2 signal corresponding to coagulative necrosis (asterisk), showing the same pattern of ablation cavity and surrounding rims as previously described, with progressive decrease in enhancement over time. A thin inner rim of low T2 signal, corresponding to hemosiderin rim (hemorrhagic congestion), can be better identified on the T2 gradient echo sequence (arrowheads—zoomed image). A thick outer rim of intermediate/low T2 signal and post-contrast enhancement (arrows) corresponds to granulation tissue/vascular fibrosis. In subsequent follow-ups, complete resolution of the lesion was observed, with only minor residual fibro-cicatricial changes.




Figure 5. A 33-year-old man. Axial T1 imaging of a subcutaneous desmoid tumor in the left gluteal region, at different time frames (a: pre-treatment; b: 6 months; c: 11 months; d: 17 months; e: 25 months). In the 6-month post-procedure images, note the ablation cavity encompassing the entire lesion, with a high T1 signal indicative of coagulative necrosis (asterisk). In this case, it is surrounded by an outer rim of intermediate T1 signal (arrow), corresponding to granulation tissue/vascular fibrosis, and an inner rim of fat tissue (arrowhead). In subsequent follow-ups, a better definition of the outer rim of granulation tissue/vascular fibrosis and a reduction in the dimensions of the ablation cavity are evident; these are progressively replaced by adipose tissue.




Figure 6. A 50-year-old woman. Axial T2 fat-sat (b, c, d, e) and post-contrast axial T1 with and without fat-sat imaging (f-i) have revealed a large, infiltrative desmoid tumor affecting the musculature and subcutaneous tissue of the left scapular region, noted for its progressive growth in control studies over the past 2 years. A computed tomography scan, performed immediately after the removal of the cryoprobes (a), displays the ice ball covering portions of the tumor. Images (b) and (f) show the pre-treatment images. At the 3-month post-procedure follow-up (c, g), a non-enhancing ablation cavity (asterisk) with high T2 signal was noted, indicative of coagulative necrosis, and a significant volume of tumor not included in the ablation zone. By the 10- (d, h) and 18-month (e, i) follow-ups, there was a notable reduction in the overall size of the lesion, including areas that were not directly ablated, possibly due to an abscopal effect of the cryoablation.




Figure 7. A 33-year-old woman. Axial diffusion-weighted imaging (a, d), apparent diffusion coefficient (ADC) maps (b, e), and post-contrast subtraction images (c, f) of a desmoid tumor in the calf in different time frames post-cryoablation (a-c: 3 months; d-f: 6 months). In early follow-up after cryotherapy, there may be areas of low ADC values, possibly due to tumor necrosis (yellow arrows in a and b; mean $0.8 \times 10^{-3} \text{ mm}^2/\text{s}$), which should not be confused with recurrence, especially when no enhancement is present. The observed peripheral enhancement (white arrows in c and f) corresponds to granulation tissue/vascular fibrosis. In the follow-up control, an increase in ADC values is observed (asterisk in e; mean $2.8 \times 10^{-3} \text{ mm}^2/\text{s}$).

A deeper understanding of the temporal evolution of these features is essential to avoid misinterpretation and guide clinical decision-making.

Emerging technologies, including artificial intelligence and radiomics, may offer tools to differentiate residual tumor from post-ablation changes. Recent studies have shown that deep learning applied to baseline MRI can predict clinical progression of DTs with high accuracy (up to 93%), suggesting a potential role for artificial intelligence-based tools in risk stratification and treatment planning.²² Finally, growing interest in cryoablation's immunomodulatory potential may support future therapeutic combinations that enhance outcomes in patients with DTs.

In conclusion, our understanding of DTs is evolving rapidly. MRI plays a central role in evaluating post-cryoablation changes and guiding patient management. DTs treated with percutaneous cryoablation exhibit a predictable sequence of imaging changes over time. Key post-treatment MRI findings include a central non-enhancing cavity of coagulative necrosis, peripheral granulation tissue with enhancement, and progressive fibrosis characterized by decreasing T2 signal and enhancement. Accurate recognition of these patterns is critical to distinguish treatment response from recurrence. Familiarity with expected imaging patterns and their timeline can help avoid misdiagnosis of recurrence and optimize treatment strategies. Future research integrating imaging biomarkers, artificial intelligence, and immunologic response will likely further refine our approach to this complex entity.

Footnotes

Conflict of interest disclosure

The authors declared that they have no conflict of interest.

References

1. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. *Pathologica*. 2021;113(2):70-84. [\[Crossref\]](#)
2. WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Soft Tissue and Bone Tumours. 5th ed. Vol 3 [Internet]. Lyon: International Agency for Research on Cancer; 2020 [cited 2025 Nov 6]. [\[Crossref\]](#)
3. Kasper B, Baumgarten C, Garcia J, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). *Ann Oncol*. 2017;28(10):2399-2408. [\[Crossref\]](#)
4. Gronchi A, Colombo C, Le Péchoux C, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group. *Ann Oncol*. 2014;25(3):578-583. [\[Crossref\]](#)
5. Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. *Eur J Cancer*. 2020;127:96-107. [\[Crossref\]](#)
6. Papalexis N, Savarese LG, Peta G, et al. The new ice age of musculoskeletal intervention: role of percutaneous cryoablation in bone and soft tissue tumors. *Curr Oncol*. 2023;30(7):6744-6770. [\[Crossref\]](#)
7. Auloge P, Garnon J, Robinson JM, et al. Percutaneous cryoablation for advanced and refractory extra-abdominal desmoid tumors. *Int J Clin Oncol*. 2021;26(6):1147-1158. [\[Crossref\]](#)
8. Yan YY, Walsh JP, Munk PL, et al. A single-center 10-year retrospective analysis of cryoablation for the management of desmoid tumors. *J Vasc Interv Radiol*. 2021;32(9):1277-1287. [\[Crossref\]](#)
9. Efrima B, Ovadia J, Drukman I, et al. Cryosurgery for symptomatic extra-abdominal desmoids. A proof of concept study. *J Surg Oncol*. 2021;124(4):627-634. [\[Crossref\]](#)
10. Saltiel S, Bize PE, Goetti P, et al. Cryoablation of extra-abdominal desmoid tumors: a single-center experience with literature review. *Diagnostics (Basel)*. 2020;10(8):556. [\[Crossref\]](#)
11. Kurtz JE, Buy X, Deschamps F, et al. CRYODESMO-O1: a prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. *Eur J Cancer*. 2021;143:78-87. [\[Crossref\]](#)
12. Bouhamama A, Lame F, Mastier C, et al. Local control and analgesic efficacy of percutaneous cryoablation for desmoid tumors. *Cardiovasc Intervent Radiol*. 2020;43(1):110-119. [\[Crossref\]](#)
13. Shinagare AB, Ramaiya NH, Jagannathan JP, et al. A to Z of desmoid tumors. *AJR Am J Roentgenol*. 2011;197(6):W1008-1014. [\[Crossref\]](#)
14. Ganeshan D, Amini B, Nikolaidis P, Assing M, Vikram R. Current update on desmoid fibromatosis. *J Comput Assist Tomogr*. 2019;43(1):29-38. [\[Crossref\]](#)
15. Okuda M, Yoshida K, Kobayashi S, Gabata T. Desmoid-type fibromatosis: imaging features and course. *Skeletal Radiol*. 2023;52(7):1293-1303. [\[Crossref\]](#)
16. Chen J, Qian W, Mu F, Niu L, Du D, Xu K. The future of cryoablation: an abscopal effect. *Cryobiology*. 2020;97:1-4. [\[Crossref\]](#)
17. Garnon J, Cazzato RL, Autrusseau PA, et al. Desmoid fibromatosis: interventional radiology (sometimes) to the rescue for an atypical disease. *Br J Radiol*. 2025;98(1170):840-850. [\[Crossref\]](#)
18. Cazzato RL, Gantzer J, de Marini P, et al. Sporadic desmoid tumours: systematic review with reflection on the role of cryoablation. *Cardiovasc Intervent Radiol*. 2022;45(5):613-621. [\[Crossref\]](#)
19. Kasper B, Baldini EH, Bonvalot S, et al. Current management of desmoid tumors: a review. *JAMA Oncol*. 2024;10(8):1121-1128. [\[Crossref\]](#)
20. Yang X, Gao X, Xu C, et al. Cryoablation synergizes with anti-PD-1 immunotherapy induces an effective abscopal effect in murine model of cervical cancer. *Transl Oncol*. 2025;51:102175. [\[Crossref\]](#)
21. Dux DM, Chodakiewicz Y, Bitton R, et al. MRI features that predict progression of residual disease after ablation of extra-abdominal desmoid fibromatosis. *Eur Radiol*. 2025;35(7):4161-4170. [\[Crossref\]](#)
22. Fares R, Atlan LD, Druckmann I, et al. Imaging-based deep learning for predicting desmoid tumor progression. *J Imaging*. 2024;10(5):122. [\[Crossref\]](#)